Your browser is no longer supported. Please, upgrade your browser.
HZNP [NASD]
Horizon Therapeutics Public Limited Company
Index- P/E37.42 EPS (ttm)2.31 Insider Own0.60% Shs Outstand226.10M Perf Week-1.81%
Market Cap19.68B Forward P/E14.46 EPS next Y5.99 Insider Trans-31.73% Shs Float222.24M Perf Month-20.19%
Income551.90M PEG2.79 EPS next Q1.37 Inst Own91.50% Short Float1.63% Perf Quarter-25.39%
Sales2.96B P/S6.65 EPS this Y-37.60% Inst Trans-0.06% Short Ratio2.22 Perf Half Y-13.66%
Book/sh19.68 P/B4.40 EPS next Y26.70% ROA7.20% Target Price142.31 Perf Year15.51%
Cash/sh4.70 P/C18.41 EPS next 5Y13.40% ROE13.50% 52W Range70.15 - 120.54 Perf YTD-19.64%
Dividend- P/FCF24.28 EPS past 5Y48.20% ROI8.90% 52W High-28.15% Beta1.12
Dividend %- Quick Ratio2.50 Sales past 5Y23.80% Gross Margin75.80% 52W Low23.45% ATR3.62
Employees1805 Current Ratio2.80 Sales Q/Q62.90% Oper. Margin18.60% RSI (14)24.10 Volatility4.00% 3.77%
OptionableYes Debt/Eq0.58 EPS Q/Q5.60% Profit Margin18.70% Rel Volume0.93 Prev Close86.85
ShortableYes LT Debt/Eq0.57 EarningsNov 03 BMO Payout0.00% Avg Volume1.63M Price86.60
Recom1.60 SMA20-11.46% SMA50-15.07% SMA200-14.66% Volume1,521,122 Change-0.29%
Dec-08-21Initiated Wells Fargo Overweight $137
Nov-19-21Upgrade Goldman Neutral → Buy $168
Oct-07-21Resumed Jefferies Buy $132
Mar-22-21Resumed Morgan Stanley Overweight $103
Mar-12-21Initiated Wolfe Research Outperform $107
Sep-09-20Initiated JP Morgan Overweight $110
Aug-27-20Initiated Citigroup Buy $112
Jan-08-20Initiated Goldman Neutral $35
Sep-26-19Initiated BofA/Merrill Buy $34
Sep-12-19Initiated Guggenheim Buy
Aug-14-19Upgrade BMO Capital Markets Market Perform → Outperform $29 → $36
May-01-19Upgrade Citigroup Neutral → Buy $21 → $32
Mar-08-19Upgrade Morgan Stanley Equal-Weight → Overweight $32
Nov-15-18Downgrade Mizuho Buy → Neutral
Jun-27-18Downgrade Citigroup Buy → Neutral
Jan-12-18Upgrade Mizuho Neutral → Buy $12 → $18
Sep-28-17Initiated Goldman Buy $16
Jun-16-17Initiated Cantor Fitzgerald Overweight $13
May-09-17Reiterated Stifel Buy $35 → $20
May-09-17Downgrade Mizuho Buy → Neutral $22 → $10
Jan-24-22 08:00AM  
Jan-19-22 09:38AM  
Jan-18-22 06:35AM  
Jan-11-22 07:45AM  
Jan-10-22 07:30AM  
Jan-07-22 08:20AM  
Jan-06-22 08:00AM  
Dec-23-21 08:00AM  
Dec-20-21 01:34PM  
Dec-16-21 08:00AM  
Dec-08-21 06:38PM  
Dec-07-21 02:30PM  
Dec-02-21 09:00AM  
08:30AM  
Dec-01-21 01:30AM  
Nov-22-21 10:13AM  
08:00AM  
Nov-19-21 07:28AM  
Nov-15-21 09:00AM  
Nov-12-21 08:33AM  
07:29AM  
Nov-09-21 08:00AM  
Nov-08-21 04:05PM  
Nov-07-21 12:57PM  
Nov-05-21 09:01AM  
Nov-04-21 01:00PM  
Nov-03-21 05:00PM  
12:55PM  
07:02AM  
07:00AM  
Nov-02-21 10:00AM  
Nov-01-21 11:05AM  
10:00AM  
Oct-27-21 08:30AM  
Oct-25-21 08:00AM  
Oct-22-21 09:29AM  
Oct-21-21 12:00PM  
Oct-15-21 08:49AM  
Oct-13-21 08:00AM  
Oct-12-21 09:00AM  
Oct-11-21 09:00AM  
08:30AM  
08:00AM  
Oct-06-21 08:00AM  
Oct-04-21 08:30AM  
08:00AM  
Sep-29-21 07:00AM  
Sep-28-21 09:14AM  
Sep-23-21 09:00AM  
08:30AM  
Sep-21-21 08:00AM  
07:30AM  
Sep-16-21 09:00AM  
Sep-07-21 08:30AM  
Sep-06-21 07:55AM  
Sep-01-21 09:10AM  
Aug-31-21 01:25PM  
Aug-23-21 04:01PM  
Aug-04-21 07:00AM  
Jul-25-21 08:45PM  
Jul-23-21 03:50AM  
Jul-22-21 12:07PM  
Jul-16-21 08:30AM  
Jul-08-21 08:00AM  
Jul-05-21 05:30AM  
Jun-30-21 08:00AM  
06:15AM  
Jun-29-21 08:00AM  
Jun-28-21 09:00AM  
Jun-21-21 12:58PM  
07:30AM  
Jun-18-21 12:30PM  
Jun-17-21 07:00AM  
Jun-08-21 04:14AM  
Jun-02-21 08:00AM  
May-27-21 08:00AM  
May-24-21 08:00AM  
May-21-21 08:00AM  
May-20-21 08:30AM  
May-13-21 11:30AM  
May-06-21 04:30PM  
08:30AM  
08:00AM  
May-05-21 12:53PM  
07:00AM  
May-04-21 01:59PM  
Apr-27-21 08:00AM  
Apr-24-21 04:44AM  
Apr-22-21 04:49PM  
Apr-21-21 07:30AM  
Apr-17-21 06:33AM  
Apr-16-21 08:30AM  
08:00AM  
Apr-12-21 03:58PM  
08:30AM  
Apr-08-21 08:00AM  
Apr-07-21 08:00AM  
Apr-05-21 08:30AM  
Mar-30-21 07:30AM  
Mar-29-21 10:05AM  
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DesJardin Michael A.EVP, Technical OperationsJan 21Option Exercise0.003,6790139,385Jan 24 05:07 PM
Hoelscher Paul W.EVP, CFOJan 21Option Exercise0.005,558070,138Jan 24 05:06 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerJan 21Option Exercise0.005,354061,665Jan 24 05:05 PM
Walbert Timothy PChairman, President and CEOJan 21Option Exercise0.0020,3360694,558Jan 24 05:04 PM
Walbert Timothy PChairman, President and CEOJan 14Option Exercise22.1425,000553,500699,222Jan 14 06:44 PM
Walbert Timothy PChairman, President and CEOJan 14Sale90.0225,0002,250,412674,222Jan 14 06:44 PM
Pasternak AndyEVP and Chief Business OfficerJan 06Sale99.577,987795,29640,972Jan 06 09:02 PM
Walbert Timothy PChairman, President and CEODec 31Option Exercise22.1425,000553,500529,482Jan 04 05:00 PM
Walbert Timothy PChairman, President and CEODec 31Sale108.0775,0008,105,487454,482Jan 04 05:00 PM
Hoelscher Paul W.EVP, CFODec 28Option Exercise15.968,575136,8579,624Dec 30 09:00 PM
Hoelscher Paul W.EVP, CFODec 28Sale110.008,575943,2501,049Dec 30 09:00 PM
Pasternak AndyEVP and Chief Business OfficerDec 07Sale100.001,525152,50021,830Dec 08 06:35 PM
McHugh Miles WSr VP & Princ. Acctg OfficerDec 01Option Exercise22.1479,4841,759,776116,005Dec 03 05:20 PM
McHugh Miles WSr VP & Princ. Acctg OfficerDec 01Sale106.6279,4848,474,58436,521Dec 03 05:20 PM
Walbert Timothy PChairman, President and CEONov 30Sale102.4050,0005,119,881504,482Dec 01 05:58 PM
Pasternak AndyEVP and Chief Business OfficerNov 04Option Exercise29.5223,251686,37053,523Nov 05 05:00 PM
MOZE BARRYEVP, Chief Admin. OfficerNov 04Option Exercise14.7775,7431,118,556151,424Nov 05 05:00 PM
MOZE BARRYEVP, Chief Admin. OfficerNov 04Sale112.2875,7438,504,20875,681Nov 05 05:00 PM
Pasternak AndyEVP and Chief Business OfficerNov 04Sale113.0430,1683,410,18123,355Nov 05 05:00 PM
Walbert Timothy PChairman, President and CEONov 01Sale118.4925,0002,962,327554,482Nov 03 04:30 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerOct 27Option Exercise7.6110,72981,64819,844Oct 29 04:55 PM
Walbert Timothy PChairman, President and CEOSep 30Sale110.3050,0005,515,140579,482Oct 01 04:08 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerSep 21Option Exercise7.6146,271352,12255,386Sep 23 05:00 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerSep 21Sale110.0046,2715,089,8109,115Sep 23 05:00 PM
Beeler Brian KEVP, General CounselSep 17Sale107.9128,1433,036,91162,775Sep 17 05:06 PM
Pasternak AndyEVP and Chief Business OfficerSep 09Option Exercise29.5223,250686,34046,604Sep 13 08:00 PM
Pasternak AndyEVP and Chief Business OfficerSep 09Sale107.8423,2502,507,26123,354Sep 13 08:00 PM
Walbert Timothy PChairman, President and CEOAug 27Option Exercise22.147,435164,611847,723Aug 27 05:00 PM
Beeler Brian KEVP, General CounselAug 16Option Exercise22.1465,8571,458,074165,816Aug 17 05:01 PM
Beeler Brian KEVP, General CounselAug 16Sale106.0074,8987,939,18890,918Aug 17 05:01 PM
Thompson Elizabeth H.Z.EVP, Research & DevelopmentAug 05Sale106.347,542802,02514,187Aug 06 05:03 PM
Walbert Timothy PChairman, President and CEOJul 30Sale101.7425,0002,543,489840,288Jul 30 04:28 PM
GREY MICHAEL GDirectorJul 22Option Exercise2.375,00011,8505,000Jul 23 05:00 PM
GREY MICHAEL GDirectorJul 22Sale100.045,000500,2000Jul 23 05:00 PM
MOZE BARRYEVP, Chief Admin. OfficerJul 08Sale92.5435,0763,246,01271,639Jul 09 05:00 PM
Walbert Timothy PChairman, President and CEOJun 01Sale91.8525,0002,296,204875,887Jun 03 04:41 PM
Hoelscher Paul W.EVP, CFOMay 14Sale90.01102,9259,263,847172,226May 14 06:12 PM
Kent JeffSee remarksMay 11Option Exercise22.1412,592278,78783,586May 12 05:02 PM
Daniel William FDirectorMay 10Option Exercise12.7020,000254,00020,000May 12 05:01 PM
Daniel William FDirectorMay 10Sale86.5620,0001,731,2750May 12 05:01 PM
Walbert Timothy PChairman, President and CEOApr 30Sale94.9825,0002,374,413899,838Apr 30 07:03 PM
GREY MICHAEL GDirectorApr 12Option Exercise2.3715,00035,55015,000Apr 13 06:03 PM
MOZE BARRYEVP, Chief Admin. OfficerApr 12Sale88.9665,6135,837,049105,665Apr 13 06:04 PM
GREY MICHAEL GDirectorApr 12Sale90.2815,0001,354,2000Apr 13 06:03 PM
Camardo Daniel A.EVP and President, U.S.Apr 05Option Exercise24.1818,281442,09351,181Apr 05 05:25 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOApr 01Option Exercise28.4037,0001,050,710123,414Apr 02 05:13 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOApr 01Sale93.5170,7396,615,09452,675Apr 02 05:13 PM
Beeler Brian KEVP, General CounselMar 31Sale90.1226,8442,419,18195,677Apr 02 05:11 PM
Camardo Daniel A.EVP and President, U.S.Mar 30Sale85.5012,9001,103,00632,900Mar 31 05:11 PM
Shannon James SamuelDirectorMar 01Option Exercise12.197,23288,1587,232Mar 03 04:46 PM
Shannon James SamuelDirectorMar 01Sale91.307,232660,2610Mar 03 04:46 PM
Walbert Timothy PChairman, President and CEOMar 01Sale91.3526,9752,464,137924,838Mar 03 04:44 PM
SANTINI GINODirectorMar 01Sale91.4712,0001,097,60023,795Mar 03 04:45 PM
DesJardin Michael A.EVP, Technical OperationsFeb 26Sale91.831,099100,92186,247Feb 26 06:12 PM
DesJardin Michael A.EVP, Technical OperationsFeb 24Sale92.4815,9441,474,44887,346Feb 26 06:12 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffFeb 22Sale87.225,698496,98781,677Feb 23 06:19 PM
Karnani VikramEVP & President, InternationalFeb 22Sale87.198,358728,722104,165Feb 23 06:20 PM
DesJardin Michael A.EVP, Technical OperationsFeb 11Sale90.0010,786970,740101,200Feb 12 05:01 PM
DesJardin Michael A.EVP, Technical OperationsFeb 02Sale85.004,530385,050111,986Feb 04 05:39 PM
Walbert Timothy PChairman, President and CEOFeb 01Option Exercise0.009,087022,895Feb 03 05:24 PM